This enduring TeleECHO podcast will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas (NMSCs). Over the course of this activity there will be discussion of the data from clinical trials assessing the clinical profiles of new systemic therapies with different mechanisms of action for the treatment of patients with advanced NMSCs failing or not amenable to surgery or radiation; integrating methods for identifying and managing side effects associated with new systemic therapies for the treatment of patients with advanced NMSCs into routine clinical practice; categorizing the types of patients with unresectable NMSCs who may benefit from new systemic therapies for the treatment of advanced NMSCs; and lastly enhancing patient management including care coordination through participation in interdisciplinary care teams for those with advanced NMSCs failing or not amenable to surgery or radiation.

RELEASED DATE: November 3, 2022
EXPIRATION DATE: November 3, 2023

This enduring activity investigates the critical role of systemic therapy, including targeted treatment and immunotherapy, in patients with advanced non-melanoma skin cancers (NMSCs) who fail or are ineligible for surgical or radiation therapy. Learn more about factors that can help determine when systemic therapy is appropriate, available, and emerging systemic treatment options, and elements of multidisciplinary care to enhance your management approach in NMSC.

RELEASED DATE: November 7, 2022
EXPIRATION DATE: November 7, 2023

FACULTY
Vishal Anil Patel, MD, FAAD, FACMS
Director of Cutaneous Oncology, GW Cancer Center
Director of Dermatologic Surgery, GW Department of Dermatology
Assistant Professor of Dermatology & Hematology/Oncology
George Washington University School of Medicine & Health Sciences
Washington, DC

Javier Cañueto Álvarez, MD, PhD
High-Risk Skin Cancer Unit
Department of Dermatology
Hospital Universitario de Salamanca
Associate Professor
Faculty of Medicine
University of Salamanca
Salamanca, Spain

PROGRAM CHAIR

David Michael Miller, MD, PhD, FAAD
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Cancer Center
Boston, MA

SPEAKER FACULTY

Kevin Emerick, MD
Associate Professor, Harvard Medical School
Co-Director of MEE/MGH Non-Melanoma Skin Cancer
Multidisciplinary Clinic
Boston, MA

This activity is designed to meet the educational needs of global oncologists, dermatologists, Mohs surgeons, and the multidisciplinary care team who care for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas.

RELEASED DATE: May 31, 2023
EXPIRATION DATE: May 31, 2024

This enduring activity will inform clinicians of the rationale for use of immunotherapy in non-melanoma skin cancer (NMSC), specifically keratinocyte carcinomas, and how immunotherapy may be a therapeutic adjunct to treatment of NMSCs. Key topics that will be covered through didactic and case-based discussions include pathophysiology, mechanisms of tumor cell dissemination and post-surgical recurrence, emerging use of immune checkpoint inhibition in the neo-adjuvant setting of cutaneous squamous cell carcinoma, as well as efficacy and safety data from studies of immunotherapy in patients with either advanced basal cell or advanced cutaneous squamous cell carcinomas.

RELEASED DATE: June 29, 2023
EXPIRATION DATE: June 29, 2024

This educational program will help healthcare providers to better examine clinical trials data supporting the use of new systemic immunotherapies for the treatment of patients with advanced nonmelanoma skin cancers (NMSCs), failing or not amenable to surgery or radiation; describe risk-assessment of patients with NMSCs who may derive greater benefit from new systemic therapies as opposed to Mohs surgery; and review the coordination and collaboration of multidisciplinary team members in the management of patients with advanced NMSCs failing or not amenable to surgery or radiation.

RELEASED DATE: June 30, 2023
EXPIRATION DATE: June 30, 2024

The Virtual Pathway activity will inform clinicians of the rationale for use of immunotherapy in cutaneous squamous cell carcinoma (cSCC), including the reasoning behind investigations of its use in the neoadjuvant or adjuvant settings. Through this interactive experience that incorporates didactic presentations, illustrative animations, and case-based discussion, clinicians will be exposed to current perspectives on the pathophysiology of early cSCC, how immunotherapy before and/or after surgery may improve outcomes, and available data from clinical study of neoadjuvant immunotherapy for cSCC.

RELEASED DATE: July 28, 2023
EXPIRATION DATE: July 28, 2024

This program will inform clinicians of the rationale for use of immunotherapy in cutaneous squamous cell carcinoma (cSCC), including the reasoning behind investigations of its use in the neoadjuvant and adjuvant settings. Through the immersive 3D animations, clinicians will be exposed to current perspectives on the pathophysiology of early cSCC, how immunotherapy before and/or after surgery may improve outcomes, and available data from clinical study of neoadjuvant immunotherapy for cSCC.

RELEASED DATE: December 15, 2023
EXPIRATION DATE: December 15, 2024

These enduring activities use a unique documentary approach to share the patient experience of diagnosis and treatment of cutaneous malignancies. It highlights their experiences with surgery, radiation, chemotherapy, and immunotherapy with commentary from our faculty expert. The goal is to help learners identify potential immune targets and systemic treatment strategies; optimize multidisciplinary management; and incorporate shared decision making in arriving at individualized care for their patients with cutaneous malignancies.

RELEASED DATE: January 31, 2024
EXPIRATION DATE: January 31, 2025